The emergence and predominance of the SARS-CoV-2 Delta strain and the data on the reduced efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine over time contributed to an increase in cases and infections even in vaccinated individuals.
Israel approved the third booster dose on July 30, 2021 to deal with the new wave of the COVID-19 pandemic.
The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Giannis Danasis, Panos Malandrakis and Thanos Dimopoulos (Rector of EKPA) summarize the latest data of the publication of R. Arbel and associates in the prestigious scientific review The New England Journal of Medicine (DOI: 10.1056 / NEJMoa2115624).
The researchers collected data from vaccinated individuals aged 50 years and older who had been vaccinated with two doses of BNT162b2 at least 5 months earlier.
Deaths were then compared between those receiving a booster dose and those not receiving a booster dose.
In total, 843,208 people were included in the study, of whom 758,118 (90%) received a third booster dose during the study (54 days).
In total, 65 deaths were recorded among those receiving the third dose (0.16 deaths per 100,000 persons per day), while 137 deaths were recorded among those who did not receive the third dose (2.98 deaths per 100,000 persons per day).
In particular, booster vaccines were 90% less likely to die from COVID-19 than those who did not receive a booster dose.
In conclusion, individuals who received a booster dose of BNT162b2 at least 5 months after the second dose of the vaccine were significantly less likely to die (90%) than those who did not receive a booster dose.
Follow Skai.gr on Google News
and be the first to know all the news
.
